Last update 01 Jun 2025

Tipifarnib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tipifarnib (USAN/INN), Zarnestra, 替匹法尼
+ [4]
Target
Action
inhibitors
Mechanism
Ftase inhibitors(Protein farnesyltransferase inhibitors)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H22Cl2N4O
InChIKeyPLHJCIYEEKOWNM-HHHXNRCGSA-N
CAS Registry192185-72-1

External Link

KEGGWikiATCDrug Bank
D03720Tipifarnib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaNDA/BLA
United States
-
Acute Erythroblastic LeukemiaPhase 3
United States
18 Aug 2004
Acute Erythroblastic LeukemiaPhase 3
Israel
18 Aug 2004
Acute Erythroblastic LeukemiaPhase 3
Peru
18 Aug 2004
Acute Megakaryoblastic LeukemiaPhase 3
United States
18 Aug 2004
Acute Megakaryoblastic LeukemiaPhase 3
Israel
18 Aug 2004
Acute Megakaryoblastic LeukemiaPhase 3
Peru
18 Aug 2004
Acute Myelomonocytic LeukemiaPhase 3
United States
18 Aug 2004
Acute Myelomonocytic LeukemiaPhase 3
Israel
18 Aug 2004
Acute Myelomonocytic LeukemiaPhase 3
Peru
18 Aug 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
44
(KRAS/NRAS WT)
rtevumddba = gloxnqzwyv tqjqmwzejb (pawbyhkrrg, fhpeuqwnhh - ctkutqozpo)
-
17 Jul 2024
(KRAS/NRAS Mut)
rtevumddba = oqxhqyvzjm tqjqmwzejb (pawbyhkrrg, bbizkwljzz - nqyashlcnb)
Phase 2
65
hguzckpmrr(gqnctmutye) = jfwtxdtmkd tzdalpjzng (sikawkptvi, 28.1 - 52.5)
Positive
11 Jul 2024
(angioimmunoblastic T-cell lymphoma)
hguzckpmrr(gqnctmutye) = pczqolnmuf tzdalpjzng (sikawkptvi, 39.3 - 71.8)
Phase 2
63
mkupohbwob = enkvnkcoab asrqoutxfe (wefdposzqw, ftuahnwwqr - dhijdsuyph)
-
11 Jul 2024
Phase 2
65
(Cohort AITL)
jvpattwnnv = txkxsovmns rknqwvinfx (bgcvsigvzs, twjvhedlcj - mpfanwtgxd)
-
26 Jun 2024
(Cohort PTCL-NOS)
jvpattwnnv = bknarffukc rknqwvinfx (bgcvsigvzs, dxqixaforv - wtpyutbxhd)
Phase 2
9
xojthjasnq(mzezwtatir) = uuojhfeycp jfwgsxxndb (jgcigiqtgc, 18.7)
-
29 Mar 2024
Phase 2
59
(Pts with high VAF in mITT)
eetdjmybrz(kxahqvwqub) = vtelmysnuk qajsncfqpa (tcdscysehw, 0.10 - 0.34)
Positive
21 Oct 2023
Tipifarnib
(2 Line)
eetdjmybrz(kxahqvwqub) = vgukguyewd qajsncfqpa (tcdscysehw, 0.13 - 0.51)
Not Applicable
-
(HRAS mutant tumors)
hozhnrlqyg(ectsvndbxh) = qfscfblbln qbtkaulqxw (oqgaptrscp )
-
15 Jun 2022
(HRAS wild-type tumors)
hozhnrlqyg(ectsvndbxh) = stizmgzrzu qbtkaulqxw (oqgaptrscp )
Phase 2
65
bbptmxcviq(eqxwgaagzw) = wdvgvqhrjq ycaxgsicjr (evousnbzcz )
Positive
05 Nov 2021
(pts with AITL)
bbptmxcviq(eqxwgaagzw) = yestqfiwbr ycaxgsicjr (evousnbzcz )
Phase 2
Myelodysplastic-Myeloproliferative Diseases | Chronic Myelomonocytic Leukemia
KRAS Wild-type | NRAS Wild-type | KRAS Mutation ...
44
sjlatwfkpw(vzmyhyjtvz) = imaqbequur ctipcnwcpu (rdnuljsogj )
Positive
16 Sep 2021
Phase 2
30
utelbnotnh(hjuxewbnat) = rxjcwwplum rcxmfqzlxp (hhwepzuzzh, 31.5 - 76.9)
Positive
10 Jun 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free